The research team analyzed records from more than 21,000 patients who received a first recorded schizophrenia diagnosis between January 2006 and November 2023, each with at least one year of continuous insurance enrollment before and after that index month. Of the 21,590 eligible patients, 15,955 had at least one psychiatric diagnosis recorded before the index month. Among those with prior diagnoses, the single most common earliest recorded condition was a depressive episode, accounting for 45.2 percent, followed by other anxiety disorders at 21.6 percent. Only 5,788 of these patients — roughly one in three — had schizophrenia itself as their first recorded psychiatric diagnosis.

That distribution matters because it quantifies what psychiatrists have long described anecdotally. Schizophrenia is a heterogeneous disorder, and affective symptoms — depression, anxiety, social withdrawal, sleep disturbance — commonly emerge before frank psychosis. When a patient presents with low mood or crippling worry, few clinicians would immediately suspect a psychotic illness that may not manifest for another year or more. The study found that the mean interval between the earliest recorded psychiatric diagnosis and the first recorded schizophrenia diagnosis was 12.8 months overall, but stretched to 20.2 months among patients whose earliest recorded diagnosis was something other than schizophrenia. In other words, for many patients, a full year and a half of clinical contact passes under a different diagnostic label before the picture clarifies.

To make fair comparisons between patients with and without prior psychiatric diagnoses, the researchers used inverse probability of treatment weighting, a statistical technique that reweights the two groups to mimic the balance of a randomized trial, adjusting for differences in age, sex, and other baseline characteristics. They then applied Cox proportional hazards models to estimate the risk of two downstream outcomes after the index month: psychiatric inpatient admission and physician-certified sick leave. The approach is standard in pharmacoepidemiology, but it hinges on the assumption that all relevant confounders are captured in the claims data — an assumption the authors acknowledge is difficult to fully satisfy with administrative records.

The results on hospitalization were nuanced. In the adjusted Cox model, patients with prior psychiatric diagnoses had a modestly lower risk of psychiatric inpatient admission, with a hazard ratio of 0.87 and a 95 percent confidence interval of 0.77 to 0.98, reaching statistical significance at P = 0.020. Yet when the team examined the same outcome using Kaplan–Meier survival curves and a patient-years analysis, the difference between groups disappeared. This kind of internal disagreement is not unusual in observational data. The Cox model adjusts for measured confounders, while the unadjusted analyses do not, so a protective signal that appears only after adjustment may reflect confounding rather than a true clinical effect. The authors are careful not to overinterpret it.

Sick leave told a cleaner and more troubling story. Across all three analytical approaches, patients with prior psychiatric diagnoses were at higher risk of physician-certified sick leave after their schizophrenia diagnosis. The Cox model yielded a hazard ratio of 1.19 (95 percent confidence interval, 1.11 to 1.27; P < 0.001), the Kaplan–Meier analysis showed highly significant differences by both log-rank and Wilcoxon tests, and the patient-years analysis produced a risk ratio of 1.09 (95 percent confidence interval, 1.04 to 1.15). Sick leave is a blunt but meaningful proxy for functional impairment — it captures the point at which symptoms become severe enough that a physician judges a patient unable to work. The consistent signal across methods suggests that patients whose schizophrenia was preceded by other psychiatric diagnoses may experience a more disruptive illness course in occupational terms.

Why might that be? One plausible reading is that a prior psychiatric diagnosis creates a longer pathway through the health system, during which the underlying psychotic process continues to evolve untreated. The field has a name for the delay between the onset of psychotic symptoms and the start of adequate treatment: the duration of untreated psychosis, or DUP. Longer DUP has been repeatedly associated with worse functional outcomes, including slower symptom remission and greater social and occupational disability. If depressive or anxiety symptoms delay recognition of emerging psychosis, the roughly 20-month gap documented in this study could represent a window in which earlier intervention might alter the trajectory. The authors stop short of claiming causality, but the temporal pattern is consistent with that interpretation.

Alternative explanations deserve equal attention. Depression and anxiety may genuinely be part of the prodromal phase of schizophrenia — early manifestations of the same neurodevelopmental process rather than misdiagnoses. Some patients may have true comorbid mood or anxiety disorders that persist alongside psychosis and independently worsen functional outcomes. And there are artifacts of the data itself to consider: claims databases record diagnoses that are billed, not necessarily diagnoses that are biologically correct, and diagnostic practice in Japan, as elsewhere, may favor affective labels in the early stages of unclear presentations. The retrospective design cannot disentangle these possibilities, and the study’s funding by Sumitomo Pharma, with several authors employed by the company or the data provider JMDC, is disclosed in the paper and should be weighed by readers.

The scale of the dataset is the study’s principal strength. JMDC claims records cover a large share of Japan’s employed population and their dependents, offering statistical power that individual clinical cohorts cannot match, and the 17-year observation window spans changes in diagnostic practice and treatment availability. The requirement of continuous enrollment for at least a year on either side of the index month reduces the risk that prior diagnoses were simply missed due to gaps in coverage. Still, the population skews toward working-age employed people, which may explain why sick leave was measurable at all — and it means the findings may not generalize to patients outside the formal labor market, older adults, or those with severe illness from the outset.

For clinicians, the practical message is one of sustained vigilance rather than alarm. The authors conclude that because depressive and anxiety disorders commonly precede a first recorded schizophrenia diagnosis in Japan, and because the mean interval between the earliest non-schizophrenia psychiatric diagnosis and the schizophrenia diagnosis is approximately 20 months, continued clinical assessment of patients presenting with mood or anxiety symptoms may be warranted — particularly when symptoms are atypical, treatment-refractory, or accompanied by social decline or unusual thinking. That is not a call to diagnose psychosis prematurely, which carries its own harms, but a reminder that a first psychiatric diagnosis is sometimes a waypoint rather than a destination. For researchers, the study offers a template for using claims data to map the diagnostic pathways that lead into severe mental illness, and a quantitative benchmark — 45 percent depression, 22 percent anxiety, 20 months — against which future early-detection strategies can be measured.

Subject of Research: Diagnostic patterns preceding a first schizophrenia diagnosis and their association with subsequent clinical outcomes in Japan

Article Title: Previous psychiatric diagnoses preceding a first recorded schizophrenia diagnosis and subsequent clinical outcomes: a retrospective study using a Japanese claims database

Article References: Takekita, Y., Azekawa, T., Baba, K., Nosaka, T., Tajima, T., Funakoshi, Y., Takamatsu, Y., & Kato, M. (2026). Previous psychiatric diagnoses preceding a first recorded schizophrenia diagnosis and subsequent clinical outcomes: a retrospective study using a Japanese claims database. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08687-6

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08687-6

Keywords: schizophrenia, depression, anxiety disorders, prodrome, claims database, psychiatric diagnosis, duration of untreated psychosis, sick leave, psychiatric hospitalization, retrospective cohort study, Japan, early detection

The design of the study is what gives it its power. Rather than comparing a single patient group with controls, the team recruited 111 adolescents spanning a gradient of risk: 25 with a diagnosis of bipolar I disorder who were currently euthymic, meaning their mood was stable at the time of testing; 32 classified as high-risk, typically because of a family history of the illness; 24 deemed ultra-high risk, showing attenuated or subclinical manic symptoms identified through instruments such as the Bipolar Prodrome Symptom Scale-Prospective; and 30 healthy controls. This four-tier structure allowed the investigators to ask whether neurocognitive alterations deepen as one moves along the continuum from familial risk toward full-threshold illness — a question that cross-sectional comparisons of patients and controls alone cannot answer.

Each participant completed a battery of behavioral tasks and questionnaires targeting four cognitive-affective domains. Risk-taking was probed with the Modified Balloon Analog Risk Task, in which participants inflate virtual balloons for points while weighing the danger of an explosion, and with the Iowa Gambling Task, a classic decision-making paradigm that requires learning, often without conscious awareness, which of several card decks yields long-term gains. Impulsivity was measured behaviorally with a Go/No-Go Task, which tests the ability to suppress a prepotent motor response, and subjectively with the Barratt Impulsivity Scale-11, a widely used self-report instrument that decomposes impulsivity into attentional, motor, and non-planning facets. Reward sensitivity was assessed with the Behavioral Inhibition/Behavioral Activation Scale, which quantifies the strength of approach and avoidance motivational systems. Finally, emotional conflict resolution was tested with an Emotional Stroop Task, in which participants must name the color of words while ignoring their emotional content, forcing the brain to resolve interference between affective salience and task demands.

The statistical approach was deliberately conservative. Group comparisons used the Kruskal-Wallis test, appropriate for non-normally distributed data, with Benjamini-Hochberg false discovery rate correction to control for multiple comparisons, and the most robust findings were further checked against the stricter Bonferroni threshold. Multinomial logistic regression, adjusted for age and sex, then tested which measures best classified adolescents into the four groups, and receiver operating characteristic analysis quantified diagnostic discrimination. This layered pipeline matters because the field of psychiatric biomarkers is littered with findings that evaporate under multiple-comparison scrutiny; here, the authors explicitly flagged which results survived which level of correction.

The standout result was accuracy on the Emotional Stroop Task. Conflict accuracy — the ability to correctly respond despite emotional interference — was the most consistent discriminator in the entire study. It separated the high-risk, ultra-high-risk, and bipolar groups from healthy controls, and, crucially, it also distinguished the bipolar group from both risk groups. In other words, deficits in resolving emotional conflict appear not merely as a consequence of the illness but as a feature that intensifies across the risk continuum, making it one of the most promising candidate markers identified. The regression analysis underscored this: emotional conflict accuracy discriminated the combined ultra-high-risk and bipolar groups from the combined healthy and high-risk groups with an area under the curve of 0.923, a level of discrimination that, if replicated, would be remarkable for a single behavioral measure in psychiatry. The authors are careful to note, however, that this cut-off is exploratory and derived from a modest sample.

Decision-making under risk also told a coherent story. Lower net scores on the Iowa Gambling Task differentiated all three clinical groups — bipolar, high-risk, and ultra-high-risk — from healthy controls, suggesting that impaired affective decision-making is a broad vulnerability feature present even before illness onset. On the Modified Balloon Analog Risk Task, a higher average number of pumps — a direct behavioral index of risk-taking — differentiated the ultra-high-risk and bipolar groups from controls in the adjusted models. Notably, this elevated risk-taking in the ultra-high-risk group correlated with concurrent subclinical manic symptoms, hinting that the balloon-pumping behavior may capture something phenomenologically close to the emerging hypomanic temperament. Group differences on the Emotional Stroop, Iowa Gambling Task, Barratt Impulsivity Scale, and Go/No-Go task survived both false discovery rate and Bonferroni correction, whereas the balloon task differences survived false discovery rate correction only.

Perhaps the most clinically useful aspect of the findings is the differential pattern across impulsivity subdomains. Non-planning impulsivity, reward sensitivity, and emotional conflict resolution deficits distinguished all three clinical groups from healthy controls, positioning them as potential trait markers of vulnerability that are present from the earliest identifiable risk stage. By contrast, motor and attentional impulsivity, fun-seeking, and response inhibition deficits were more specific to the ultra-high-risk and bipolar groups, appearing only as adolescents move closer to or into full-threshold illness. This dissociation suggests a staged model of neurocognitive deterioration: a baseline vulnerability layer shared across the risk spectrum, overlaid by a later-emerging layer of inhibitory and attentional dyscontrol that may signal imminent transition. If longitudinal studies confirm this architecture, clinicians could in principle use the profile of deficits — not just their presence — to estimate where along the risk pathway a given adolescent sits.

The theoretical implications reach into long-standing models of bipolar disorder. Heightened reward sensitivity and approach motivation have been central to psychological theories of mania, and the present findings align with the idea that a hyperactive behavioral activation system, combined with impaired top-down regulation of emotional interference, creates a cognitive environment in which mood dysregulation can escalate. The anterior cingulate cortex, a region heavily implicated in conflict monitoring and error processing, is a plausible neural substrate for the Emotional Stroop deficits observed, and its dysfunction could plausibly link the affective and cognitive disturbances that characterize the bipolar prodrome. The authors themselves frame these alterations as candidate markers rather than established ones, a distinction that reflects both the strength and the limits of the evidence.

Those limits deserve emphasis. The study is cross-sectional, meaning it captures a snapshot rather than a trajectory; it cannot prove that the observed deficits predict who will convert from risk to illness, only that they covary with risk stage at a single point in time. The sample, while thoughtfully stratified, is modest — 111 adolescents across four groups — and the ultra-high-risk subgroup in particular is small. The authors also note that the striking area under the curve of 0.923 for emotional conflict accuracy should be treated as a hypothesis-generating estimate, since classification metrics derived from the same dataset used for discovery are prone to optimism. Longitudinal follow-up of high-risk and ultra-high-risk cohorts, ideally with neuroimaging and repeated cognitive assessment, will be needed to determine whether these candidate markers genuinely forecast onset and whether early intervention targeting emotional regulation could alter the course of the illness.

Even with those caveats, the study represents a meaningful step toward a long-sought goal in child and adolescent psychiatry: identifying measurable, task-based signals that stratify bipolar risk before the first full manic episode. Bipolar disorder in young people is frequently misdiagnosed, often as unipolar depression or attention deficit hyperactivity disorder, and treatment delays carry substantial costs in academic, social, and neurobiological terms. A validated cognitive profile — impaired emotional conflict resolution, compromised affective decision-making, and stage-specific impulsivity changes — could eventually complement clinical interviews and family history to sharpen risk assessment. For now, the message from Ankara and Izmir is one of cautious optimism: the cognitive fingerprints of bipolar vulnerability appear to be detectable in adolescence, arranged along a gradient that mirrors the illness itself, and waiting to be tested against the passage of time.

Subject of Research: Neurocognitive vulnerability markers across bipolar disorder risk stages in adolescents

Article Title: Neurocognitive candidate markers across bipolar disorder risk stages in adolescents

Article References: Akpınar, S., Kafali, H. Y., Kabasakal, İ., Kaya, H., Akman, A. Ö., Bora, E., & Dinç, G. Ş. (2026). Neurocognitive candidate markers across bipolar disorder risk stages in adolescents. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08732-4

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08732-4

Keywords: bipolar disorder, adolescents, ultra-high risk, emotional conflict, reward sensitivity, impulsivity, risk-taking, Iowa Gambling Task, Emotional Stroop Task, neuropsychology, prodrome, predictive markers